Chloroform Extraction, Phytochemical Screening, GC-HRMS Analysis and Computational Investigation of Ehretia Laevis Roxb. as Potential MELK Inhibitor for the Treatment of Cancer

Publish Year: 1404
نوع سند: مقاله ژورنالی
زبان: English
View: 142

This Paper With 22 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_CHM-9-8_007

تاریخ نمایه سازی: 11 خرداد 1404

Abstract:

Maternal embryonic leucine zipper kinase (MELK), a serine/threonine kinase, plays a vital role in cancer progression by regulating cell proliferation, apoptosis, and stem cell maintenance. It is often overexpressed in various cancers, including breast cancer and glioblastoma, making it an attractive target for cancer therapies. Ehretia laevis Roxb (Boraginaceae), commonly known as Ajan Vruksha, is a renowned medicinal plant in Ayurveda that is traditionally used for treating reproductive and digestive disorders. In this study, we aimed to explore the anticancer potential of Ehretia laevis Roxb against MELK. The chloroform extract was obtained by fractional extraction, followed by fractionation using column chromatography and thin-layer chromatography (TLC). Qualitative chemical analysis was conducted, and the extract was subjected to GC-HRMS analysis to identify potential phytoconstituents. A total of ۳۴ compounds were identified and evaluated through computational analysis of the MELK protein (PDB ID: ۵IH۹). Several compounds exhibited excellent binding affinities, suggesting their potential as MELK inhibitors. Further in-depth ADMET analysis revealed five promising compounds as potent MELK inhibitors. Among these, Compound ۱۲ (۲-Methyl-۲-phenyl-۵-(۱,۴-dihydropyridin-۴-ylidene)-۱,۳-dioxan-۴,۶-dione) demonstrated the highest binding affinity (-۸.۷ kcal/mol. It forms a stable complex with the target protein, establishing one carbon-hydrogen bond with Glu۸۷ and multiple hydrophobic interactions with Leu۲۷, Ile۱۴۹, Tyr۸۸, Cys۸۹, Val۲۵, Lys۴۰, Ile۱۷, Ala۳۸, and Pro۹۰. This study highlights the potential of compound ۱۲ as a novel MELK inhibitor, paving the way for further investigation in various in vitro and in vivo models to assess its clinical applicability.

Authors

Sunayana R. Vikhe

Department of Pharmacognosy, Pravara Rural College of Pharmacy, Loni, Maharashtra ۴۱۳۷۳۶, India

Sambodhi Patil

Department of Pharmacognosy, Pravara Rural College of Pharmacy, Loni, Maharashtra ۴۱۳۷۳۶, India

Rajashree Ghogare

Department of Pharmacognosy, Pravara Rural College of Pharmacy, Loni, Maharashtra ۴۱۳۷۳۶, India

Hassan A Madkhali

Department of Pharmacology and Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia

Mohd Masih Uzzaman Khan

Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraidah ۵۱۴۵۲, Saudi Arabia

Mohd Nazam Ansari

Department of Pharmacology and Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia

S. Shakila Banu

Periyar College of Pharmaceutical Sciences, Tiruchirappalli, Tamil Nadu ۶۲۰۰۲۱, India

Lavanya Yaidikar

Department of Pharmacology, Seven Hills College of Pharmacy, Venkataramapuram, Tanapalli, Tirupati, Andhra Pradesh ۵۱۷۵۶۱, India

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :